---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-26-000116"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2026-11-10T21:50:52+00:00"
generated_at: "2026-11-10T21:52:05.189965+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio files first NDA for seralutinib in PAH; Q3 net loss $48.1M, cash $51.2M

## Summary
- NDA for seralutinib in PAH submitted to FDA in September 2026, backed by Phase 3 PROSERA plus Phase 2 TORREY; FDA acceptance would unlock ~$125M.
- Q3 2026 revenue from collaborators $38.4M vs $13.3M a year earlier, driven by $25.1M recognized on the July 2026 Chiesi collaboration termination.
- Net loss $48.1M ($7.36/share) vs $48.2M ($16.92/share) in Q3 2025; R&D fell to $18.8M from $45.5M on lower seralutinib trial costs; G&A $9.6M.
- Cash, equivalents and marketable securities $51.2M at Sept 30, 2026, down from $57.0M at June 30; structured placement delivered $25M upfront.
- 1-for-80 reverse stock split completed September 2026 to regain Nasdaq minimum bid price compliance; trading continues as GOSS.

## SEC filing metadata
- accession: 0001728117-26-000116
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2026-11-10T21:50:52+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811726000116/0001728117-26-000116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811726000116/goss-20261110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-26-000116
- JSON: https://secwatch.observer/filing/0001728117-26-000116.json
- Plain text: https://secwatch.observer/filing/0001728117-26-000116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.